MT1|cas:2060573-82-0|西域试剂

MT1,98.37%

产品编号：Bellancom-111976| CAS NO：2060573-82-0| 分子式：C₅₄H₆₆Cl₂N₁₀O₉S₂| 分子量：1134.20

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-111976	￥2500.00	杭州北京（现货）
Bellancom-111976	￥6500.00	杭州北京（现货）
Bellancom-111976	￥10500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MT1

产品介绍

MT1 是 BET bromodomains 的化学探针，其对BRD4(1) 的 IC₅₀ 值为 0.789 nM。

生物活性

MT1 is a bivalent chemical probe of BET bromodomains, with an IC₅₀ of 0.789 nM for BRD4(1).

体外研究

MT1 (100 nM, 24 h) significantly induces apoptosis via caspase-3 and PARP in MV4;11 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	MV4;11 cells.
Concentration:	100 nM.
Incubation Time:	24 h.
Result:	Significant apoptosis was observed by caspase-3 and PARP cleavage after treatment.

体内研究
(In Vivo)

MT1 (44.2 and 22.1 µmol/kg, ip daily, for 14 days) significantly delayed leukemia progression in mice (Mus musculus) compared to JQ1.
MT1 exhibits terminal t_1/2 of 2.70 h in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Leukemia xenograft models.
Dosage:	44.2 and 22.1 µmol/kg.
Administration:	Intraperitoneally for 14 subsequent days.
Result:	Significantly reduced leukemic burden over the course of the study compared to either vehicle or JQ1.

体内研究

MT1 (44.2 and 22.1 µmol/kg, ip daily, for 14 days) significantly delayed leukemia progression in mice (Mus musculus) compared to JQ1.
MT1 exhibits terminal t_1/2 of 2.70 h in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Leukemia xenograft models.
Dosage:	44.2 and 22.1 µmol/kg.
Administration:	Intraperitoneally for 14 subsequent days.
Result:	Significantly reduced leukemic burden over the course of the study compared to either vehicle or JQ1.

体内研究

MT1 (44.2 and 22.1 µmol/kg, ip daily, for 14 days) significantly delayed leukemia progression in mice (Mus musculus) compared to JQ1.
MT1 exhibits terminal t_1/2 of 2.70 h in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Leukemia xenograft models.
Dosage:	44.2 and 22.1 µmol/kg.
Administration:	Intraperitoneally for 14 subsequent days.
Result:	Significantly reduced leukemic burden over the course of the study compared to either vehicle or JQ1.

性状

Solid

溶解性数据

In Vitro:

DMSO : 150 mg/mL (132.25 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.8817 mL	4.4084 mL	8.8168 mL
5 mM	0.1763 mL	0.8817 mL	1.7634 mL
10 mM	0.0882 mL	0.4408 mL	0.8817 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 7.5 mg/mL (6.61 mM); Clear solution

此方案可获得 ≥ 7.5 mg/mL (6.61 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 75.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 7.5 mg/mL (6.61 mM); Suspended solution; Need ultrasonic

此方案可获得 7.5 mg/mL (6.61 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 75.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 7.5 mg/mL (6.61 mM); Clear solution

此方案可获得 ≥ 7.5 mg/mL (6.61 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 75.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。